-
公开(公告)号：US10669287B2
公开(公告)日：2020-06-02
申请号：US16087017
申请日：2017-03-21
Applicant: JAPAN SCIENCE AND TECHNOLOGY AGENCY
Inventor： Motomu Kanai , Yohei Soma , Jizhi Ni , Atsuhiko Taniguchi
Abstract: Provided is a compound which is bioapplicable and amyloid-selective, and is useful as an amyloid oxygenation catalyst applicable not only to Aβ peptides but also to other amyloids, and a preventive/therapeutic drug for an amyloid-related disease using the same. A curcumin-boron complex represented by the following formula (1): wherein X1 and X2 are identical or different, and each represent a halogenoalkyl group or a halogen atom; X3 represents a bromine atom, an iodine atom, or a selenium atom; R1 and R2 are identical or different, and each represent a hydrogen atom or an optionally substituted alkyl group; R3 and R4 are identical or different, and each represent a hydrogen atom, a halogen atom, an alkoxy group, or an optionally substituted alkyl group, or R1 and R3 or R2 and R4 are optionally taken together to form an optionally substituted alkylene group or alkenylene group; R5 and R6 are identical or different, and each represent a hydrogen atom or an optionally substituted alkyl group; R7 and R8 are identical or different, and each represent a hydrogen atom, a halogen atom, an alkoxy group, or an optionally substituted alkyl group, or R5 and R7 or R6 and R8 are optionally taken together to form an optionally substituted alkylene group or alkenylene group; and m and n each represent an integer of 1 to 3, or a salt thereof.
-
公开(公告)号：US10035831B2
公开(公告)日：2018-07-31
申请号：US14898409
申请日：2014-06-13
Applicant: JAPAN SCIENCE AND TECHNOLOGY AGENCY
Inventor： Motomu Kanai , Yohei Soma , Atsuhiko Taniguchi , Daisuke Sasaki
CPC classification number: C07K14/4711 , A61K38/00 , C07K1/113
Abstract: The invention provides an Aβ peptide aggregation inhibitor, an Aβ peptide toxicity reducing agent, and a preventive and/or therapeutic agent for Alzheimer's disease. The oxidized Aβ peptide in which one or more amino acid residues of Aβ peptide have been oxidized (excluding an oxidized Aβ peptide in which only Met has been oxidized).
-
公开(公告)号：US11643448B2
公开(公告)日：2023-05-09
申请号：US16018447
申请日：2018-06-26
Applicant: JAPAN SCIENCE AND TECHNOLOGY AGENCY
Inventor： Motomu Kanai , Yohei Soma , Atsuhiko Taniguchi , Daisuke Sasaki
CPC classification number: C07K14/4711 , C07K1/113 , A61K38/00
Abstract: The invention provides an Aβ peptide aggregation inhibitor, an Aβ peptide toxicity reducing agent, and a preventive and/or therapeutic agent for Alzheimer's disease. The oxidized Aβ peptide in which one or more amino acid residues of Aβ peptide have been oxidized (excluding an oxidized Aβ peptide in which only Met has been oxidized).
-
Patent Agency Ranking
公开(公告)号：US09932333B2
公开(公告)日：2018-04-03
申请号：US15326320
申请日：2015-07-15
Applicant: JAPAN SCIENCE AND TECHNOLOGY AGENCY
Inventor： Motomu Kanai , Yohei Soma , Atsuhiko Taniguchi , Yusuke Shimizu
IPC: C07D455/04 , C07D417/04
CPC classification number: C07D455/04 , A61K31/4725 , A61K31/4745 , A61K38/00 , C07D417/04 , C07K7/06 , C07K14/47
Abstract: It is intended to provide: a compound useful as an amyloid oxidation catalyst which is applicable in vivo and is applicable not only to Aβ peptides but to other amyloids; and a prophylactic or therapeutic drug for an amyloid-related disease, comprising the same. The present invention provides a benzothiazole compound represented by the following formula (1) wherein X represents a halogen atom; R1 represents an optionally substituted hydrocarbon group; R2 represents a hydrogen atom or an optionally substituted hydrocarbon group; R3 and R4 are the same or different and each represent a hydrogen atom, an optionally substituted hydrocarbon group, an alkoxy group, a halogen atom, an amino group, a nitro group, or a cyano group; R2 and R4 optionally together form an alkylene group; and R5 represents an anion.
-
公开(公告)号：US10626128B2
公开(公告)日：2020-04-21
申请号：US16087017
申请日：2017-03-21
Applicant: JAPAN SCIENCE AND TECHNOLOGY AGENCY
Inventor： Motomu Kanai , Yohei Soma , Jizhi Ni , Atsuhiko Taniguchi
Abstract: Provided is a compound which is bioapplicable and amyloid-selective, and is useful as an amyloid oxygenation catalyst applicable not only to Aβ peptides but also to other amyloids, and a preventive/therapeutic drug for an amyloid-related disease using the same. A curcumin-boron complex represented by the following formula (1): wherein X1 and X2 are identical or different, and each represent a halogenoalkyl group or a halogen atom; X3 represents a bromine atom, an iodine atom, or a selenium atom; R1 and R2 are identical or different, and each represent a hydrogen atom or an optionally substituted alkyl group; R3 and R4 are identical or different, and each represent a hydrogen atom, a halogen atom, an alkoxy group, or an optionally substituted alkyl group, or R1 and R3 or R2 and R4 are optionally taken together to form an optionally substituted alkylene group or alkenylene group; R5 and R6 are identical or different, and each represent a hydrogen atom or an optionally substituted alkyl group; R7 and R8 are identical or different, and each represent a hydrogen atom, a halogen atom, an alkoxy group, or an optionally substituted alkyl group, or R5 and R7 or R6 and R8 are optionally taken together to form an optionally substituted alkylene group or alkenylene group; and m and n each represent an integer of 1 to 3, or a salt thereof.
-
公开(公告)号：US10526348B2
公开(公告)日：2020-01-07
申请号：US16087017
申请日：2017-03-21
Applicant: JAPAN SCIENCE AND TECHNOLOGY AGENCY
Inventor： Motomu Kanai , Yohei Soma , Jizhi Ni , Atsuhiko Taniguchi
Abstract: Provided is a compound which is bioapplicable and amyloid-selective, and is useful as an amyloid oxygenation catalyst applicable not only to Aβ peptides but also to other amyloids, and a preventive/therapeutic drug for an amyloid-related disease using the same. A curcumin-boron complex represented by the following formula (1): wherein X1 and X2 are identical or different, and each represent a halogenoalkyl group or a halogen atom; X3 represents a bromine atom, an iodine atom, or a selenium atom; R1 and R2 are identical or different, and each represent a hydrogen atom or an optionally substituted alkyl group; R3 and R4 are identical or different, and each represent a hydrogen atom, a halogen atom, an alkoxy group, or an optionally substituted alkyl group, or R1 and R3 or R2 and R4 are optionally taken together to form an optionally substituted alkylene group or alkenylene group; R5 and R6 are identical or different, and each represent a hydrogen atom or an optionally substituted alkyl group; R7 and R8 are identical or different, and each represent a hydrogen atom, a halogen atom, an alkoxy group, or an optionally substituted alkyl group, or R5 and R7 or R6 and R8 are optionally taken together to form an optionally substituted alkylene group or alkenylene group; and m and n each represent an integer of 1 to 3, or a salt thereof.
-
公开(公告)号：US10188671B2
公开(公告)日：2019-01-29
申请号：US15555721
申请日：2016-03-04
Applicant: JAPAN SCIENCE AND TECHNOLOGY AGENCY
Inventor： Motomu Kanai , Yohei Soma , Yusuke Shimizu , Atsuhiko Taniguchi , Kounosuke Oisaki , Yoichiro Kuninobu
IPC: A61K31/69 , C07F5/02 , A61P25/28 , A61P3/10 , A61P25/16 , C07D401/14 , C07D455/04 , C07D207/44 , C07D207/456 , A61K31/4025 , A61K31/4725 , C07D207/46 , C07D215/06 , A61K41/00
Abstract: Provided is a compound which is useful as an in vivo applicable, amyloid-oxygenating catalyst selective for amyloid and applicable not only to an Aβ peptide, but also to other amyloids and a drug containing the compound for preventing and/or treating amyloid-related diseases. Disclosed is a boron-dipyrrin complex represented by the following formula (1)
-
公开(公告)号：US20180312558A1
公开(公告)日：2018-11-01
申请号：US16018447
申请日：2018-06-26
Applicant: JAPAN SCIENCE AND TECHNOLOGY AGENCY
Inventor： Motomu Kanai , Yohei Soma , Atsuhiko Taniguchi , Daisuke Sasaki
CPC classification number: C07K14/4711 , A61K38/00 , C07K1/113
Abstract: The invention provides an Aβ peptide aggregation inhibitor, an Aβ peptide toxicity reducing agent, and a preventive and/or therapeutic agent for Alzheimer's disease. The oxidized Aβ peptide in which one or more amino acid residues of Aβ peptide have been oxidized (excluding an oxidized Aβ peptide in which only Met has been oxidized).
-
-
-
-
-
-
-
Search Results
8
records
(took 0.029 seconds)
